血浆miR-145在结直肠癌中的表达及临床意义

Expression of plasma miR-145 in colorectal cancer and its clinical significance

目的研究miR145在结直肠癌患者和健康者血浆中的表达差异，并探讨其与临床特征之间的关系。方法收集53例初治结直肠癌患者和26例健康者外周血浆，提取总RNA，用反转录及real—timePCR检测miR145的表达情况，分析其与临床特征之间的关系，评估其对结直肠癌的诊断效能。结果miR145在结直肠癌患者血浆中的表达较健康者显著降低（P〈001），miR145的AUC为0859，鉴别结直肠癌患者的敏感性868％、特异性885％，但miR145的表达水平与临床特征（性别、年龄、肿瘤位置、淋巴结状态、TNM分期、局部浸润深度及CEA水平）之间均无相关性（均P〉0．05）。结论血浆miR145有望作为结直肠癌的新型标记物，但可能只参与了结直肠癌发生的起始过程。

Objective To investigate the plasma expression of miR-145 in patients with colorectal cancer and its clinical significance. Methods The plasma levels of miR-145 in 53 patients with colorectal cancer and 26 healthy subjects were mea- sured using real-time quantitative PCR. The relationship between miR-145 expression and clinical characteristics of colorectal cancer was analyzed. The diagnostic value of miR-145 for colorectal cancer was evaluated. Results The plasma miR-145 lev- els were decreased significantly in colorectal cancer patients （P〈0.01）. The AUC （the area under the ROC curve） of miR-145 was 0.859 with a 86.8% sensitivity and 88.5% specificity in discriminating colorectal cancer from normal subjects; however, the expression levels of miR-145 were not associated with the gender, age, tumor location, nodal status, TNM staging, T-classifica- tion and CEA levels of patients （P 〉0.05）. Conclusion A decreased plasma miR-145 levels are detected in patients with col- orectal cancer, which suggests miR-145 might be used as a potential tumor-marker for colorectal cancer.